MedTrace Logo

MitoQ for Fatigue in Multiple Sclerosis

NCT03166800 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-04-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after study drug initiation will assess if MitoQ has a significant change in fatigue.

Conditions

Interventions

DRUG

Mitoquinone

This arm of the intervention the study subject will be administered 40mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.

DRUG

Mitoquinone

This arm of the intervention the study subject will be administered 20mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.

DRUG

Placebo

This arm of the intervention the study subject will be administered placebo capsules to orally take every morning for 12 weeks.

Sponsors & Collaborators

  • MitoQ Limited

    collaborator UNKNOWN

  • National Multiple Sclerosis Society

    collaborator OTHER

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Vijayshree Yadav, MD · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-15
Primary Completion
2019-01-10
Completion
2019-01-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03166800 on ClinicalTrials.gov